Advances in clinical application of nanoparticle-based therapy for cancer treatment: A systematic review
Background: Due to the rapid development of nanotechnology and nanocomplex synthetic techniques, a large number of nanoparticle-based cancer medicines have been evaluated or applied in clinical trials for utility. However, the quality, efficiency and adverse events of these trials are sometimes cont...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2024-12-01
|
| Series: | Nano TransMed |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2790676024000074 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850251314321162240 |
|---|---|
| author | Pingchuan Ma Guanru Wang Ke Men Chunjie Li Ning Gao Longjiang Li |
| author_facet | Pingchuan Ma Guanru Wang Ke Men Chunjie Li Ning Gao Longjiang Li |
| author_sort | Pingchuan Ma |
| collection | DOAJ |
| description | Background: Due to the rapid development of nanotechnology and nanocomplex synthetic techniques, a large number of nanoparticle-based cancer medicines have been evaluated or applied in clinical trials for utility. However, the quality, efficiency and adverse events of these trials are sometimes controversial. Our systematic review aimed to better summary the current nanoparticle-related randomized controlled trials for cancer treatment, assess their quality and analyze the outcomes reported. Methods: A comprehensive search was performed in electronic database as follows: PubMed, Embase, the Cochrane Library and Web of Science, until February 2024. We then identified the randomized controlled trials (RCTs) that investigate the nanoparticle-based therapy versus placebo, ordinary chemotherapy, standard of care or different doses of nanoparticles in cancer patients. The information, primary outcomes and adverse events records of trials were extracted. Results: 31 RCTs were included, Inside, 22 studies used paclitaxel related nanoparticle in their RCTs, including 18 trials of nanoparticle albumin-bound (nab)-paclitaxel. A total of 10399 patients were enrolled for evaluation. Most of the included trials were ranked as excellent or good quality after assessed according to CONSORT checklist. The treatment efficiency reflected via progression-free survival (PFS), overall survival (OS), and pathological complete response (pCR) were not significantly superior to control arm. Lymphopenia, leucopenia and neutropenia were the most common complications in paclitaxel-related therapies. Conclusions: According to current trials, the advantages of nanoparticles-based therapy were not significant compared to ordinary chemotherapy schedule no matter in efficiency or safety for cancer treatment. The majority of nanomedicine currently in evaluation is chemotherapy medicine related, lacking of the attempts of other treatment strategy. Thus, it is urgent to broaden the therapy strategy applied in nanoparticle utility for cancer treatment exploration. |
| format | Article |
| id | doaj-art-2f268e10cfdc432aa62ae405fee9db19 |
| institution | OA Journals |
| issn | 2790-6760 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | KeAi Communications Co., Ltd. |
| record_format | Article |
| series | Nano TransMed |
| spelling | doaj-art-2f268e10cfdc432aa62ae405fee9db192025-08-20T01:57:55ZengKeAi Communications Co., Ltd.Nano TransMed2790-67602024-12-01310003610.1016/j.ntm.2024.100036Advances in clinical application of nanoparticle-based therapy for cancer treatment: A systematic reviewPingchuan Ma0Guanru Wang1Ke Men2Chunjie Li3Ning Gao4Longjiang Li5State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, ChinaState Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, ChinaState Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province 610041, ChinaState Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, ChinaState Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, China; Correspondence to: State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, No.14,3 Rd Section Of Ren Min Nan Rd, Chengdu, Sichuan 610041, China.State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, China; Correspondence to: State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, No.14,3 Rd Section Of Ren Min Nan Rd, Chengdu, Sichuan 610041, China.Background: Due to the rapid development of nanotechnology and nanocomplex synthetic techniques, a large number of nanoparticle-based cancer medicines have been evaluated or applied in clinical trials for utility. However, the quality, efficiency and adverse events of these trials are sometimes controversial. Our systematic review aimed to better summary the current nanoparticle-related randomized controlled trials for cancer treatment, assess their quality and analyze the outcomes reported. Methods: A comprehensive search was performed in electronic database as follows: PubMed, Embase, the Cochrane Library and Web of Science, until February 2024. We then identified the randomized controlled trials (RCTs) that investigate the nanoparticle-based therapy versus placebo, ordinary chemotherapy, standard of care or different doses of nanoparticles in cancer patients. The information, primary outcomes and adverse events records of trials were extracted. Results: 31 RCTs were included, Inside, 22 studies used paclitaxel related nanoparticle in their RCTs, including 18 trials of nanoparticle albumin-bound (nab)-paclitaxel. A total of 10399 patients were enrolled for evaluation. Most of the included trials were ranked as excellent or good quality after assessed according to CONSORT checklist. The treatment efficiency reflected via progression-free survival (PFS), overall survival (OS), and pathological complete response (pCR) were not significantly superior to control arm. Lymphopenia, leucopenia and neutropenia were the most common complications in paclitaxel-related therapies. Conclusions: According to current trials, the advantages of nanoparticles-based therapy were not significant compared to ordinary chemotherapy schedule no matter in efficiency or safety for cancer treatment. The majority of nanomedicine currently in evaluation is chemotherapy medicine related, lacking of the attempts of other treatment strategy. Thus, it is urgent to broaden the therapy strategy applied in nanoparticle utility for cancer treatment exploration.http://www.sciencedirect.com/science/article/pii/S2790676024000074NanoparticleCancer treatmentNanoparticle albumin-bound-paclitaxelNanomedicine |
| spellingShingle | Pingchuan Ma Guanru Wang Ke Men Chunjie Li Ning Gao Longjiang Li Advances in clinical application of nanoparticle-based therapy for cancer treatment: A systematic review Nano TransMed Nanoparticle Cancer treatment Nanoparticle albumin-bound-paclitaxel Nanomedicine |
| title | Advances in clinical application of nanoparticle-based therapy for cancer treatment: A systematic review |
| title_full | Advances in clinical application of nanoparticle-based therapy for cancer treatment: A systematic review |
| title_fullStr | Advances in clinical application of nanoparticle-based therapy for cancer treatment: A systematic review |
| title_full_unstemmed | Advances in clinical application of nanoparticle-based therapy for cancer treatment: A systematic review |
| title_short | Advances in clinical application of nanoparticle-based therapy for cancer treatment: A systematic review |
| title_sort | advances in clinical application of nanoparticle based therapy for cancer treatment a systematic review |
| topic | Nanoparticle Cancer treatment Nanoparticle albumin-bound-paclitaxel Nanomedicine |
| url | http://www.sciencedirect.com/science/article/pii/S2790676024000074 |
| work_keys_str_mv | AT pingchuanma advancesinclinicalapplicationofnanoparticlebasedtherapyforcancertreatmentasystematicreview AT guanruwang advancesinclinicalapplicationofnanoparticlebasedtherapyforcancertreatmentasystematicreview AT kemen advancesinclinicalapplicationofnanoparticlebasedtherapyforcancertreatmentasystematicreview AT chunjieli advancesinclinicalapplicationofnanoparticlebasedtherapyforcancertreatmentasystematicreview AT ninggao advancesinclinicalapplicationofnanoparticlebasedtherapyforcancertreatmentasystematicreview AT longjiangli advancesinclinicalapplicationofnanoparticlebasedtherapyforcancertreatmentasystematicreview |